136 related articles for article (PubMed ID: 10353606)
1. Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors.
Picon A; Bertagna X; de Keyzer Y
Oncogene; 1999 Apr; 18(16):2627-33. PubMed ID: 10353606
[TBL] [Abstract][Full Text] [Related]
2. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression.
Newell-Price J; King P; Clark AJ
Mol Endocrinol; 2001 Feb; 15(2):338-48. PubMed ID: 11158338
[TBL] [Abstract][Full Text] [Related]
3. Isolation and initial characterization of the BRCA2 promoter.
Davis PL; Miron A; Andersen LM; Iglehart JD; Marks JR
Oncogene; 1999 Oct; 18(44):6000-12. PubMed ID: 10557089
[TBL] [Abstract][Full Text] [Related]
4. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
5. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter.
Rotheneder H; Geymayer S; Haidweger E
J Mol Biol; 1999 Nov; 293(5):1005-15. PubMed ID: 10547281
[TBL] [Abstract][Full Text] [Related]
6. An E2F binding sequence negatively regulates the response of the insulin-like growth factor 1 (IGF-I) promoter to simian virus 40T antigen and to serum.
Porcu P; Graña X; Li S; Swantek J; De Luca A; Giordano A; Baserga R
Oncogene; 1994 Aug; 9(8):2125-34. PubMed ID: 8035997
[TBL] [Abstract][Full Text] [Related]
7. Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1.
Darbinian N; Gallia GL; Kundu M; Shcherbik N; Tretiakova A; Giordano A; Khalili K
Oncogene; 1999 Nov; 18(46):6398-402. PubMed ID: 10597240
[TBL] [Abstract][Full Text] [Related]
8. E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M.
Polzin RG; Benlhabib H; Trepel J; Herrera JE
Gene; 2004 Oct; 341():209-18. PubMed ID: 15474303
[TBL] [Abstract][Full Text] [Related]
9. Complexes containing the retinoblastoma gene product recognize different DNA motifs related to the E2F binding site.
Ouellette MM; Chen J; Wright WE; Shay JW
Oncogene; 1992 Jun; 7(6):1075-81. PubMed ID: 1534398
[TBL] [Abstract][Full Text] [Related]
10. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F.
Ohtani K; Iwanaga R; Nakamura M; Ikeda M; Yabuta N; Tsuruga H; Nojima H
Oncogene; 1999 Apr; 18(14):2299-309. PubMed ID: 10327050
[TBL] [Abstract][Full Text] [Related]
11. Induction by herpes simplex virus of free and heteromeric forms of E2F transcription factor.
Hilton MJ; Mounghane D; McLean T; Contractor NV; O'Neil J; Carpenter K; Bachenheimer SL
Virology; 1995 Nov; 213(2):624-38. PubMed ID: 7491786
[TBL] [Abstract][Full Text] [Related]
12. A new component of the transcription factor DRTF1/E2F.
Girling R; Partridge JF; Bandara LR; Burden N; Totty NF; Hsuan JJ; La Thangue NB
Nature; 1993 Mar; 362(6415):83-7. PubMed ID: 8446173
[TBL] [Abstract][Full Text] [Related]
13. Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter.
Araki K; Nakajima Y; Eto K; Ikeda MA
Oncogene; 2003 Oct; 22(48):7632-41. PubMed ID: 14576826
[TBL] [Abstract][Full Text] [Related]
14. Regulation of E2F-1 gene expression in avian cells.
Espanel X; Le Cam L; North S; Sardet C; Brun G; Gillet G
Oncogene; 1998 Aug; 17(5):585-94. PubMed ID: 9704924
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus E4 open reading frame 4-induced dephosphorylation inhibits E1A activation of the E2 promoter and E2F-1-mediated transactivation independently of the retinoblastoma tumor suppressor protein.
Mannervik M; Fan S; Ström AC; Helin K; Akusjärvi G
Virology; 1999 Apr; 256(2):313-21. PubMed ID: 10191196
[TBL] [Abstract][Full Text] [Related]
16. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
O'Connor RJ; Schaley JE; Feeney G; Hearing P
Oncogene; 2001 Apr; 20(15):1882-91. PubMed ID: 11313936
[TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
18. Rb may act as a transcriptional co-activator in undifferentiated F9 cells.
Bocco JL; Reimund B; Chatton B; Kedinger C
Oncogene; 1993 Nov; 8(11):2977-86. PubMed ID: 8414500
[TBL] [Abstract][Full Text] [Related]
19. E2F and GATA-1 are required for the Sertoli cell-specific promoter activity of the follicle-stimulating hormone receptor gene.
Kim JS; Griswold MD
J Androl; 2001; 22(4):629-39. PubMed ID: 11451360
[TBL] [Abstract][Full Text] [Related]
20. A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer.
Suzuki M; Okuyama S; Okamoto S; Shirasuna K; Nakajima T; Hachiya T; Nojima H; Sekiya S; Oda K
Oncogene; 1998 Aug; 17(7):853-65. PubMed ID: 9780002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
